Issue 18, 2023

Aptamer-based technology for gastric cancer theranostics

Abstract

Gastric cancer is one of the most common causes of cancer death worldwide. This cancer exhibits high molecular and phenotype heterogeneity. The overall survival rate for gastric cancer is very low because it is always diagnosed in the advanced stages. Therefore, early detection and treatment are of great significance. Currently, biomedical studies have tapped the potential clinical applicability of aptamer-based technology for gastric cancer diagnosis and targeted therapy. Herein, we summarize the enrichment and evolution of relevant aptamers, followed by documentation of the recent developments in aptamer-based techniques for early diagnosis and precision therapy for gastric cancers.

Graphical abstract: Aptamer-based technology for gastric cancer theranostics

Article information

Article type
Minireview
Submitted
18 Marts 2023
Accepted
13 Apr. 2023
First published
14 Apr. 2023

Anal. Methods, 2023,15, 2142-2153

Aptamer-based technology for gastric cancer theranostics

Q. Lv, H. Cui and X. Song, Anal. Methods, 2023, 15, 2142 DOI: 10.1039/D3AY00415E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements